STEAP1 is overexpressed in cancers: A promising therapeutic target.

Jérôme Moreaux 1, * Alboukadel Kassambara 2 Dirk Hose 3 Bernard Klein 2, 4
* Corresponding author
1 INSERM U1040
IRB - Institut de recherche en biothérapie, Cellules souches normales et cancéreuses
Abstract : The six-transmembrane epithelial antigen of prostate (STEAP) protein was identified in advanced prostate cancer and is up-regulated in multiple cancer cell lines, including prostate, bladder, colon, ovarian, and Ewing sarcoma. STEAP1 was described as a suitable antigen for T-cell-based or antibody-based immunotherapy. We have investigated the expression of STEAP1 in 40 human tumor types - brain, epithelial, lymphoid - and in their normal tissue counterparts using publicly available gene expression data, including the Oncomine Cancer Microarray database. STEAP1 was found significantly overexpressed in 11 cancers. In addition, high STEAP1 expression was associated with poor overall survival in colorectal cancer, diffuse large B cell lymphoma, acute myeloid leukemia and multiple myeloma. Taken together, these data suggest that STEAP1 is a potential therapeutic target for T-cell based immunotherapy or antibody therapy in a large panel of cancers.
docType_s :
Journal articles
Biochemical and Biophysical Research Communications, Elsevier, 2012, epub ahead of print. <10.1016/j.bbrc.2012.10.123>


http://www.hal.inserm.fr/inserm-00760262
Contributor : Monique Frei <>
Submitted on : Monday, December 3, 2012 - 4:00:07 PM
Last modification on : Monday, October 13, 2014 - 3:00:43 PM

File

Papier_STEAP1_HAL_Inserm.pdf
fileSource_public_author

Identifiers

Collections

Citation

Jérôme Moreaux, Alboukadel Kassambara, Dirk Hose, Bernard Klein. STEAP1 is overexpressed in cancers: A promising therapeutic target.. Biochemical and Biophysical Research Communications, Elsevier, 2012, epub ahead of print. <10.1016/j.bbrc.2012.10.123>. <inserm-00760262>

Export

Share

Metrics

Consultation de
la notice

143

Téléchargement du document

2